- Home
- RLX vs AUPH Comparison
RLX vs AUPH Comparison
Compare RLX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | AUPH |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RLX | AUPH |
|---|---|---|
| Price | $1.69 | $16.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 3.0M | 741.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $55.89 | $17.54 |
| Revenue Next Year | $15.07 | $15.74 |
| P/E Ratio | ★ $28.09 | $31.31 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $1.67 | $10.34 |
| 52 Week High | $2.68 | $19.25 |
Technical Indicators
Market Signals| Indicator | RLX | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 53.18 |
| Support Level | $1.67 | $15.65 |
| Resistance Level | $2.08 | $17.02 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 25.00 | 51.53 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.